386 related articles for article (PubMed ID: 31473473)
1. Dual VEGFR-2/PIM-1 kinase inhibition towards surmounting the resistance to antiangiogenic agents via hybrid pyridine and thienopyridine-based scaffolds: Design, synthesis and biological evaluation.
Rizk OH; Teleb M; Abu-Serie MM; Shaaban OG
Bioorg Chem; 2019 Nov; 92():103189. PubMed ID: 31473473
[TBL] [Abstract][Full Text] [Related]
2. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Abouzid KAM; Al-Ansary GH; El-Naggar AM
Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and docking study of pyridine and thieno[2,3-b] pyridine derivatives as anticancer PIM-1 kinase inhibitors.
Abdelaziz ME; El-Miligy MMM; Fahmy SM; Mahran MA; Hazzaa AA
Bioorg Chem; 2018 Oct; 80():674-692. PubMed ID: 30064079
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of new thieno[2,3-b]pyridine derivatives as pim-1 inhibitors.
Naguib BH; El-Nassan HB
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1718-25. PubMed ID: 27541740
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
Nafie MS; Amer AM; Mohamed AK; Tantawy ES
Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
[TBL] [Abstract][Full Text] [Related]
7. New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study.
Farrag AM; Ibrahim MH; Mehany ABM; Ismail MMF
Bioorg Chem; 2020 Dec; 105():104378. PubMed ID: 33099167
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
9. New Approaches for the Uses of Cyclohexan-1,4-dione for the Synthesis of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-b]pyridine Derivatives used as Potential Anti-prostate Cancer Agents and Pim-1 Kinase Inhibitors.
Mohareb RM; Abdo NYM; El-Sharkawy KA
Anticancer Agents Med Chem; 2018; 18(12):1736-1749. PubMed ID: 29866019
[TBL] [Abstract][Full Text] [Related]
10. Selective VEGFR-2 inhibitors: Synthesis of pyridine derivatives, cytotoxicity and apoptosis induction profiling.
AbdelHaleem A; Mansour AO; AbdelKader M; Arafa RK
Bioorg Chem; 2020 Oct; 103():104222. PubMed ID: 32889383
[TBL] [Abstract][Full Text] [Related]
11. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
12. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.
Casillas AL; Toth RK; Sainz AG; Singh N; Desai AA; Kraft AS; Warfel NA
Clin Cancer Res; 2018 Jan; 24(1):169-180. PubMed ID: 29084916
[No Abstract] [Full Text] [Related]
15. Synthesis and Biological Evaluation of Novel 4,5,6,7-Tetrahydrobenzo[D]-Thiazol-2- Yl Derivatives Derived from Dimedone with Anti-Tumor, C-Met, Tyrosine Kinase and Pim-1 Inhibitions.
Mohareb RM; Abouzied AS; Abbas NS
Anticancer Agents Med Chem; 2019; 19(12):1438-1453. PubMed ID: 31038076
[TBL] [Abstract][Full Text] [Related]
16. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
17. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
18. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
19. Heterocyclization of 2-Arylidenecyclohexan-1,3-dione: Synthesis of Thiophene, Thiazole, and Isoxazole Derivatives with Potential Antitumor Activities.
Abdo NYM; Mohareb RM; Al-Darkazali WN
Anticancer Agents Med Chem; 2020; 20(3):335-345. PubMed ID: 31362693
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
